Lyme borreliosis is the most common vector-borne disease in the United States and Europe, presenting a growing health care problem in Northern Hemisphere countries worldwide. The number of lyme disease cases in the US increased by approximately 200% in the last two decades. CDC estimates that only 1/10 of actual Lyme cases are properly reported due to lack of efficient diagnostic tools.
The current two-tier serological test using for diagnosis of lyme disease has low sensitivity of 46.3% in early lyme disease patients. In an attempt to understand variations in Humoral response in different stages of borrelia infection, we have designed a peptide microarray of entire genomes of three Borrelia strains – Borrelia burgdorferi, Borrelia garnii and Borrelia afzeli. The 16 mers peptides of proteins with overlapping of 4 AA were imprinted on the protein chip.
From this study we would also like to know how much % of the open reading frame (ORF) products (Orfs) of B. burgdorferi in the array detectably elicited an antibody response in humans with natural infections at different stages of disease. From this unbiased epitome mapping of whole genome using peptide microarray technology can leads to the identification of biologically and clinically relevant target structures in the borrelia. More importantly we can look for different footprints of several epitope (IgG, IgM, IgE) patterns from different borrelial strains in different population mix.
This study has potential to give an idea regarding global immune response around the world. The common and highly immunogenic sites detected in this study from different stages of lyme disease can be useful in developing better diagnostic tools and understanding lyme disease.